European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111653" target="_blank" >RIV/00843989:_____/25:E0111653 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/25:A2603DMR
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0923753425000584?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0923753425000584?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.annonc.2025.01.022" target="_blank" >10.1016/j.annonc.2025.01.022</a>
Alternative languages
Result language
angličtina
Original language name
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
Original language description
Background: Primary plasma cell leukemia (PPCL) is the most aggressive disorder among plasma cell malignancies, with new diagnostic criteria recently established by the International Myeloma Working Group. Studies have shown that PPCL patients receiving a combination of novel agents, but not eligible for transplantation, may have a median survival up to 2 years, extended to 3 years or more in those undergoing transplant procedures. These findings remain unsatisfactory, particularly if compared with progresses obtained in multiple myeloma. Design: A European Myeloma Network (EMN) expert panel reviewed the most recent literature and selected the areas of major concern in the management of PPCL by generating and rank ordering key questions using the criterion of clinical relevance. Multistep procedures were utilized to achieve a consensus on recommendations. The Delphi questionnaire method was used and a consensus of at least 80% was reached for all final statements. Results: An extended overview of current biological, clinical, prognostic, and therapeutic aspects of PPCL, including ongoing and close to start clinical trials, is presented. Furthermore, updated guidelines for the management of PPCL and practical recommendations are provided, in the context of current knowledge about this disease, also looking at possible future perspectives to ameliorate the outcome of these patients. Conclusions: PPCL still remains an unmet clinical need. Notwithstanding, some not negligible progresses have been recently achieved. The European Myeloma Network panel strongly support ongoing and planned clinical trials, as well as biological studies based on novel technologies, strategies, and treatment options that could represent breakthroughs we have been waiting for too long.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of oncology
ISSN
0923-7534
e-ISSN
1569-8041
Volume of the periodical
36
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
14
Pages from-to
361-374
UT code for WoS article
001456684700001
EID of the result in the Scopus database
2-s2.0-85219529807